CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Since SHIN1 has modest efficacy in vivo due to drug clearance33, we treated patient-derived CML CD34+ cells as depicted above, and transplanted them into sub-lethally irradiated NRGW mice (Fig. 6d).